1-5 of 5
Simone Jueliger
Close
Sort by
Journal Articles

Epigenetic Priming By Hypomethylation Enhances the Immunogenic Potential of Tolinapant in T-Cell Lymphoma

George Ward, Zhiqiang Zhang, Simone Jueliger, Ilya Potapov, Matthew P Davis, Adam Boxall, Jason A Taylor, Harold N. Keer, Andrea Biondo, John F Lyons, Martin Sims, Tomoko Smyth
Journal: Blood
Blood (2023) 142 (Supplement 1): 1439.
https://doi.org/10.1182/blood-2023-186712
Published: 2023
Journal Articles

ASTX660-01 Phase 2: A Case Study of Tolinapant-Induced Pseudoprogression in CTCL

Brian Poligone, Simone Jueliger, Matthew P Davis, Ilya Potapov, George Ward, Tomoko Smyth, Jason A Taylor, Harold N. Keer, Martin Sims
Journal: Blood
Blood (2023) 142 (Supplement 1): 6205.
https://doi.org/10.1182/blood-2023-179195
Published: 2023
Journal Articles

Combining the IAP Antagonist Tolinapant with a DNA Hypomethylating Agent Enhances Immunogenic Cell Death in Preclinical Models of T-Cell Lymphoma

George A. Ward, Simone Jueliger, Martin Sims, Matthew Davis, Adam Boxall, Harpreet Saini, Jason A. Taylor, Andrea Biondo, John F. Lyons, Tomoko Smyth
Journal: Blood
Blood (2021) 138 (Supplement 1): 3986.
https://doi.org/10.1182/blood-2021-152176
Published: 2021
Journal Articles

Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment

Marie Sebert, MD, Cecile Bally, Pierre Peterlin, MD, Odile Beyne-Rauzy, MD PhD, Laurence Legros, MDPhD, marie Pierre Gourin, MD PhD, Laurence Sanhes, MD, Eric Wattel, MDPhD, Emmanuel Gyan, MD PhD, Sophie Park, MD PhD, Aspasia Stamatoullas, MD, Anne Banos, Kamel Laribi, Simone Jueliger, PhD, Luke Bevan, Cendrine Chaffaut, Rosa Sapena, Benedicte Samey, Fatiha Chermat, Sylvie Chevret, Lionel Ades, MD PhD, Pierre Fenaux, MD PhD
Journal: Blood
Blood (2016) 128 (22): 347.
https://doi.org/10.1182/blood.V128.22.347.347
Published: 2016
Journal Articles

Identification of Novel Methylation Biomarkers to Predict Clinical Response to SGI-110, a Second Generation Hypomethylating Agent (HMA), in Patients with Acute Myeloid Leukaemia (AML)

Simone Jueliger, PhD, John F Lyons, PhD, Joern Lewin, PhD, Mohammad Azab, MD, Pietro Taverna, PhD
Journal: Blood
Blood (2014) 124 (21): 1050.
https://doi.org/10.1182/blood.V124.21.1050.1050
Published: 2014